ANTICOV

An open-label, multi-centre, randomized, adaptive platform trial of the safety and efficacy of several therapies versus control in mild/moderate cases of COVID-19

The ANTICOV study aims to identify one or two treatments that could be used to treat mild and moderate cases of COVID-19, to stop the disease from getting more serious. The goal of the study is to find a treatment to help avoid mass hospitalizations in low-resource settings where health systems have limited intensive care facilities.

 

Primary objective: The primary objective is to compare the efficacy of alternative treatment strategies versus control on the risk of progression to severe respiratory disease

Type of study: Interventional; Phase III, treatment; adaptative (i.e., new treatment arms can be added)

Treatment tested: Currently recruiting for NTZ+CIC treatment arm; future arms being prepared

Countries: Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, Tanzania, and Uganda

Sample size: Up to 3000 patients

Study participants: Adults over 18 years with mild or moderate COVID-19

Study status: Recruiting

More information

 

Last updated: April 2021

 

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.

Join the coalition
We are looking for individuals and institutions who want to lend their commitment and expertise to fast-track COVID-19 research in low-resource settings
Join us